Kolinesteraz İnhibitörlerinin Alzheimer Hastalığı Tedavisindeki Rolü

Year 2024, Volume: 2 Issue: 1, 42 - 45, 29.02.2024

Muhammet Gürkan Kurban , Murat Şentürk

https://doi.org/10.61845/agrimedical.1375889

Cited By: 1

Abstract

Alzheimer Hastalığı (AH) günümüzde demansın en sık görülen nedeni olup özellikle yaşlı popülasyonda sıklıkla görülen bir nörodejeneratif bozukluktur. Prevalansının zamanla artması nedeniyle AH Dünya Sağlık Örgütü tarafından da ciddi bir sağlık problemi olarak belirtilmiştir. Günümüzde AH etiyolojisi tam olarak aydınlatılamamışsa da oluşumunda rol oynayan etmenlerden bazıları bilinmektedir. AH tedavi stratejisinde kolinerjik hipotez önemli bir yol açmıştır. Bu hipoteze göre geliştirilen tedavi stratejisini sinaptik yarıkta azalmış asetilkolin düzeyini arttırmak için asetilkolinesteraz ve butirilkolinesteraz olmak üzere iki kolinesterazın inhibisyonu oluşturmaktadır. Rivastigmin, galantamin ve donepezil günümüzde AH tedavisinde bu amaçla kullanılmakta olan ilaçlardır. Ancak bu ilaçların tedavi süresinin sınırlı olması ve yan etki profillerinin geniş olması yeni tedavileri gerektirmektedir.

Keywords

Alzheimer, Kolinesteraz, Demans, İnhinitör

References

• Xie W, Stribley JA, Chatonnet A, et al. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther. 2000;293(3):896-902.
• Lanctôt KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. CMAJ. 2003;169(6):557-564.
• Gaugler J, James B, Johnson T, et al. Alzheimer’s disease facts and figures. Alzheimers Dement. 2019;15(3):321-387.
• Monteiro AR, Barbosa DJ, Remião F, Silva R. Alzheimer’s disease: Insights and new prospects in disease pathophysiology, biomarkers and disease-modifying drugs. Biochem Pharmacol. 2023;211:115522.
• Tarı Ö, Yağmurtaşan, R. Alzheimer hastalığı ve anti-Alzheimer etkili bileşiklerin yapılarının araştırılması. Hacettepe University Journal of the Faculty of Pharmacy. 2023;43(2):150-173.
• Gao S, Lima D. A review of the application of deep learning in the detection of Alzheimer’s disease. Int J Cogn Comput Engineer. 2021;3:1-8.
• Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I. Efns guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010;17(10):1236-48.
• Jessen F. Novel neuroimaging perspectives in the diagnosis of dementia. Nervenarzt. 2008;79 (3):129-136.
• Hillmann A, Hahn S, Schilling S, et al. No improvement after chronic ibuprofen treatment in the 5XFAD mouse model of Alzheimer’s disease. Neurobiol Aging. 2012;33(4):833-e39.
• Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200-8.
• Khan SS, Bloom GS. Tau: The center of a signaling nexus in Alzheimer’s disease. Front Neurosci. 2016;10:31.
• Özkan GÖ. Alzheimer hastalığında flavonoidlerin etkisi. Sağlık Bilimleri ve Yaşam Dergisi. 2022;6(1):26-38.
• Barage SH, Sonawane KD. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer’s disease. Neuropeptides. 2015;52:1-18.
• Akiyama H. Inflammation and Alzheimer’s disease, Neurobiol Aging. 2000;21(3):383-421.
• Guo J, Yu J, Grass D, de Beer FC, Kindy MS. Inflammation-dependent cerebral deposition of serum amyloid a protein in a mouse model of amyloidosis. J Neurosci. 2002;22(14):5900- 5909.
• Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM. Alzheimer’s disease: Targeting the cholinergic system. Curr Neuropharmacol. 2016;14(1):101-115.
• Demir Z, Türkan F. Asetilkolinesteraz ve bütirilkolinesteraz enzimlerinin Alzheimer hastalığı ile ilişkisi. Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi. 2022;12(4):2386-2395.
• Darvesh S, Hopkins D, Geula, C. Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003;(4):131-138.
• Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT. The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease. Brain. 2018;141(7):1917- 33.
• Herrmann N, Chau SA, Kircanski I, Lanctot KL. Current and emerging drug treatment options for Alzheimer’s disease: a systematic review. Drugs. 2011;71(15):2031-65.
• Seltzer B. Galantamine-ER for the treatment of mild-to-moderate Alzheimer’s disease. Clin Interv Aging. 2010;5:1-6.
• Dimitrova DS, Getova DP. Effects of galantamine and donepezil on active and passive avoidance tests in rats with induced hypoxia. J Pharmacol Sci. 2006;101(3):199-204.
• Loy C, Schneider L. Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev. 2006;2006(1):CD001747.
• Wu Z, Zhao L, Chen X, Cheng X, Zhang Y. Galantamine attenuates amyloid-beta deposition and astrocyte activation in APP/PS1 transgenic mice. Exp Gerontol. 2015;72:244-50.
• Sharma K. Cholinesterase inhibitors as Alzheimer’s therapeutics (Review). Mol Med Rep. 2019;20(2):1479-1487.
• Kumar A, Gupta V, Sharma S. Donepezil. [Updated 2023 Aug 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm. nih.gov/books/NBK513257/
• Yüksel N. Alzheimer hastalığının ilaçla tedavisi. Klinik Psikiyatri Dergisi. 2000;3(2):137-41.
• Potkin SG, Anand R, Fleming K, Alva G, Keator D, Carreon D. Brain metabolic and clinical effects of rivastigmine in alzheimer’s disease. Int J Neuropsychopharmacol. 2001;4(3):223-30.
• Patel PH, Gupta V. Rivastigmine. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/ books/NBK557438/
• Korabecny J, Zemek F, Soukup O, et al. Chapter 1 - Pharmacotherapy of Alzheimer’s Disease: Current State and Future Perspectives, in Drug Design and Discovery in Alzheimer’s Disease. R. Atta ur and M.I. Choudhary (Editors). 2014, Elsevier. p. 3-39.
• Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Efficacy of acetylcholinesterase inhibitors in Alzheimer’s disease. Neuropharmacol. 2021;190:108352.
• Xing S, Li Q, Xiong B, et al. Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer’s disease, and fat metabolism. Med Res Rev. 2021;41(2):858-901.
• Alzheimer’s Association. 2017 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2017;13(4):325-373.
• Zhou S, Huang G. The biological activities of butyrylcholinesterase inhibitors. Biomed Pharmacother. 2022;146:112556.
• Li S, Li AJ, Travers J, et al. Identification of compounds for butyrylcholinesterase inhibition. SLAS Discov. 2021;26(10):1355-1364.
• Jiang CS, Ge YX, Cheng ZQ et al. Discovery of new selective butyrylcholinesterase (BChE) inhibitors with Anti-Aβ aggregation activity: Structure-based virtual screening, hit optimization and biological evaluation. Molecules. 2019;24(14):2568.